Sermorelin vs Ipamorelin

Side-by-side comparison of Sermorelin, Ipamorelin — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute Sermorelin Sermorelin Acetate (GHRH 1-29) Growth Hormone Ipamorelin Ipamorelin (Selective GHRP) Growth Hormone
Basics
Molecular type GHRH AnalogueGrowth Hormone Releasing Peptide (GHRP)
Amino acids 295
Molecular weight 3,357.9 Da711.9 Da
Half-life ~10–20 min~2 hours
Route(s) Subcutaneous, IV (diagnostic only)Subcutaneous, Intramuscular
Mechanism & Research
Primary mechanism Sermorelin binds GHRH receptors in the anterior pituitary with similar affinity to native GHRH and stimulates GH synthesis and secretion. Its mechanism is essentially identical to endogenous GHRH — it is distinguished pr… Ipamorelin activates growth hormone secretagogue receptors (GHSR-1a) in the pituitary, triggering pulsatile GH release. Unlike first-generation GHRPs (GHRP-6, GHRP-2), ipamorelin's selectivity for GHSR-1a is high enough …
Research status Research Compound Research Compound
Evidence summary Sermorelin has more human clinical data than any other GHRH analogue due to its period of FDA approval. Adult studies have examined it for age-related GH decline, body composition, and sleep quality. Ipamorelin was among the first highly selective GHRPs to enter research. Phase 1 trials confirmed its clean hormonal profile. It remains a reference GHRP in comparative studies and is widely used as the GHRP component in…
Protocol & Dosing
Typical dose 200–500 mcg100–300 mcg per injection
Frequency Once daily at bedtime2–3x daily (or 1x at bedtime)
Duration 3–6 months8–12 weeks on, 4 weeks off
Timing Bedtime (maximises nocturnal GH pulse)Fasted state or 2+ hours post-meal for maximum GH response; bedtime dosing utilises natural nocturnal GH pulse
Safety
Common side effects
  • Injection site pain/redness
  • Flushing
  • Headache
  • Dizziness (rare)
  • Water retention (mild)
  • Tingling/numbness (extremities)
  • Headache (transient)
  • Injection site redness
Contraindications
  • Active malignancy
  • Hypothyroidism (treat first)
  • Pregnancy
  • Active malignancy
  • Uncontrolled diabetes
  • Pregnancy
Anti-doping Prohibited (WADA S2) Prohibited (WADA S2)
Deeper reading
Related peptides CJC-1295, Ipamorelin, Tesamorelin CJC-1295, GHRP-2, Sermorelin, Tesamorelin
Full profile Read full Sermorelin profile → Read full Ipamorelin profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.